Abstract
BackgroundParadigm shifting next-generation immuno-oncology therapeutics such as CAR-T cells and bispecific engagers are rapidly gaining interest as investigational therapies. However, the discovery and preclinical development of these therapies involve 2-D...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
